131 related articles for article (PubMed ID: 18269344)
1. Targeting signaling pathways in ovarian cancer.
Reibenwein J; Krainer M
Expert Opin Ther Targets; 2008 Mar; 12(3):353-65. PubMed ID: 18269344
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
4. Promising molecular targets in ovarian cancer.
Blagden S; Gabra H
Curr Opin Oncol; 2009 Sep; 21(5):412-9. PubMed ID: 19553815
[TBL] [Abstract][Full Text] [Related]
5. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
7. Target-based therapies in breast cancer: current status and future perspectives.
Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
[TBL] [Abstract][Full Text] [Related]
8. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer.
Frederick PJ; Straughn JM; Alvarez RD; Buchsbaum DJ
Gynecol Oncol; 2009 Jun; 113(3):384-90. PubMed ID: 19232697
[TBL] [Abstract][Full Text] [Related]
9. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?
Fischer B; Marinov M; Arcaro A
Cancer Treat Rev; 2007 Jun; 33(4):391-406. PubMed ID: 17368733
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody therapy of ovarian cancer.
Nicodemus CF; Berek JS
Expert Rev Anticancer Ther; 2005 Feb; 5(1):87-96. PubMed ID: 15757441
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
Duncan TJ; Al-Attar A; Rolland P; Scott IV; Deen S; Liu DT; Spendlove I; Durrant LG
Clin Cancer Res; 2008 May; 14(10):3030-5. PubMed ID: 18483368
[TBL] [Abstract][Full Text] [Related]
12. TrkB as a therapeutic target for ovarian cancer.
Siu MK; Wong OG; Cheung AN
Expert Opin Ther Targets; 2009 Oct; 13(10):1169-78. PubMed ID: 19694498
[TBL] [Abstract][Full Text] [Related]
13. The future of targeted therapies in ovarian cancer.
Banerjee S; Gore M
Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
[TBL] [Abstract][Full Text] [Related]
14. Targeted trials in ovarian cancer.
Ledermann JA; Raja FA
Gynecol Oncol; 2010 Oct; 119(1):151-6. PubMed ID: 20591473
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for ovarian cancer.
Lorusso D; Pietragalla A; Mainenti S; Di Legge A; Amadio G; Scambia G
Expert Opin Emerg Drugs; 2010 Dec; 15(4):635-52. PubMed ID: 20604741
[TBL] [Abstract][Full Text] [Related]
16. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.
Baron AT; Wilken JA; Haggstrom DE; Goodrich ST; Maihle NJ
IDrugs; 2009 May; 12(5):302-8. PubMed ID: 19431095
[TBL] [Abstract][Full Text] [Related]
17. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
Bertoni E; Salvadori M
J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
[TBL] [Abstract][Full Text] [Related]
18. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
Markman M
Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
[TBL] [Abstract][Full Text] [Related]
19. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
Markman M
Trends Pharmacol Sci; 2008 Oct; 29(10):515-9. PubMed ID: 18760845
[TBL] [Abstract][Full Text] [Related]
20. Role of hedgehog signaling in ovarian cancer.
Bhattacharya R; Kwon J; Ali B; Wang E; Patra S; Shridhar V; Mukherjee P
Clin Cancer Res; 2008 Dec; 14(23):7659-66. PubMed ID: 19047091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]